COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -11.56% | -22.97% | -1.00% | 30.24% | 43.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.56% | -22.97% | -1.00% | 30.24% | 43.41% |
| Cost of Revenue | 5.12% | 0.62% | -34.36% | -25.89% | -18.53% |
| Gross Profit | -30.35% | -47.20% | 179.62% | 881.72% | 896.20% |
| SG&A Expenses | 17.30% | 52.07% | -16.29% | 15.91% | 77.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.60% | -13.58% | 25.01% | 81.61% | 193.37% |
| Operating Income | 29.91% | 4.52% | -93.68% | -198.95% | -2,077.17% |
| Income Before Tax | 57.26% | 38.48% | -323.97% | -1,192.27% | -3,079.05% |
| Income Tax Expenses | -97.78% | -86.90% | 157.51% | 154.83% | 132.38% |
| Earnings from Continuing Operations | 58.47% | 38.75% | -1,115.10% | -3,949.35% | -1,716.18% |
| Earnings from Discontinued Operations | 1,215.19% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 123.08% | 32.34% | -1,200.70% | -4,160.78% | -1,811.79% |
| EBIT | 29.91% | 4.52% | -93.68% | -198.95% | -2,077.17% |
| EBITDA | 8.76% | -22.93% | -383.06% | -520.11% | -835.52% |
| EPS Basic | 110.90% | 26.68% | -272.96% | -112.35% | -118.42% |
| Normalized Basic EPS | -1.37% | -24.41% | -19.86% | 22.11% | 15.73% |
| EPS Diluted | 110.87% | 26.68% | -272.49% | -112.23% | -118.28% |
| Normalized Diluted EPS | -1.37% | -24.41% | -19.86% | 22.11% | 15.73% |
| Average Basic Shares Outstanding | 36.66% | 53.87% | 15.71% | 39.18% | 34.16% |
| Average Diluted Shares Outstanding | 36.66% | 53.87% | 15.71% | 39.18% | 34.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |